| Mrs Tonya Mayers-sherman, FNP-C | |
|
1401 River Rd, Greenwood, MS 38930-4030 | |
| (662) 459-1234 | |
| Not Available |
| Full Name | Mrs Tonya Mayers-sherman |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 1401 River Rd, Greenwood, Mississippi |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023686458 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 903666 (Mississippi) | Primary |
| Entity Name | Seshadri Raju, M.d., Pa. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174556377 PECOS PAC ID: 3971674896 Enrollment ID: O20080620000344 |
News Archive
Students of the Medicine Degree at the CEU UCH University in Castellón, Iván Echeverria and Carlos Galera-Román, and the student of the International Doctorate School of the CEU, Alejandro Fuertes-Saiz, have presented two pieces of research at the third edition of the International Congress of Dual Disorders, which was held in Madrid on June 19-22.
Repligen Corporation today announced positive results from a Phase 1 study to evaluate the pharmacokinetic (PK) and safety profile of RG3039, a novel small molecule drug candidate for the potential treatment of spinal muscular atrophy (SMA).
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.
Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device.
Although the causes of Alzheimer's disease are not completely understood, amyloid-beta (A-beta) is widely considered a likely culprit - the "sticky" protein clumps into plaques thought to harm brain cells.
› Verified 4 days ago
| Entity Name | Advanced Medical, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205900958 PECOS PAC ID: 1254532542 Enrollment ID: O20240122003811 |
News Archive
Students of the Medicine Degree at the CEU UCH University in Castellón, Iván Echeverria and Carlos Galera-Román, and the student of the International Doctorate School of the CEU, Alejandro Fuertes-Saiz, have presented two pieces of research at the third edition of the International Congress of Dual Disorders, which was held in Madrid on June 19-22.
Repligen Corporation today announced positive results from a Phase 1 study to evaluate the pharmacokinetic (PK) and safety profile of RG3039, a novel small molecule drug candidate for the potential treatment of spinal muscular atrophy (SMA).
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.
Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device.
Although the causes of Alzheimer's disease are not completely understood, amyloid-beta (A-beta) is widely considered a likely culprit - the "sticky" protein clumps into plaques thought to harm brain cells.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Tonya Mayers-sherman, FNP-C 644 Southern Oaks Dr, Florence, MS 39073-9455 Ph: (601) 906-8064 | Mrs Tonya Mayers-sherman, FNP-C 1401 River Rd, Greenwood, MS 38930-4030 Ph: (662) 459-1234 |
News Archive
Students of the Medicine Degree at the CEU UCH University in Castellón, Iván Echeverria and Carlos Galera-Román, and the student of the International Doctorate School of the CEU, Alejandro Fuertes-Saiz, have presented two pieces of research at the third edition of the International Congress of Dual Disorders, which was held in Madrid on June 19-22.
Repligen Corporation today announced positive results from a Phase 1 study to evaluate the pharmacokinetic (PK) and safety profile of RG3039, a novel small molecule drug candidate for the potential treatment of spinal muscular atrophy (SMA).
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.
Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device.
Although the causes of Alzheimer's disease are not completely understood, amyloid-beta (A-beta) is widely considered a likely culprit - the "sticky" protein clumps into plaques thought to harm brain cells.
› Verified 4 days ago
Ms. Kara Austin, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1401 River Rd, Greenwood, MS 38930 Phone: 662-459-7000 | |
William Jesse Hodnett Iii, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1401 River Rd, Greenwood, MS 38930 Phone: 662-459-7000 | |
Mrs. Sabrina Brown Matthews, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1401 River Rd, Greenwood, MS 38930 Phone: 662-459-7000 | |
Heather Henderson Wilkey, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 706 Highway 82 W, Suite B, Greenwood, MS 38930 Phone: 662-459-2181 Fax: 662-459-2182 | |
Mrs. Brandy G Smith, FNP-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2901 Highway 82 E, Greenwood, MS 38930 Phone: 662-374-2185 Fax: 662-374-2195 | |
Stacey D Sprayberry, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2901 Us 82, Greenwood, MS 38930 Phone: 662-453-6323 Fax: 662-453-9238 |